Currently patients with glioblastoma have a median survival of approximately 14.6 months and 5-year survival rates below 5%.
Voranigo plus Temodar was safe in glioma with IDH1/2 mutations. Among patents with IDH1- or IDH2-mutant glioma, the treatment ...
Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...
Early data indicate Voranigo (vorasidenib) is being rapidly adopted in patients with isocitrate dehydrogenase–mutated glioma, ...
Recent real-world study findings have identified a potential unmet need for an effective early treatment with minimal ...
Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback